All Oncology News

The FDA has finalized guidance on the use of metastasis-free survival as an end point in clinical trials for nonmetastatic castration-resistant prostate cancer.

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.

Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.

With more oral cancer therapies available, the importance of medication adherence and education must be recognized.

Polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with diffuse large B-cell lymphoma.

Understanding the functionality and naming convention of biosimilars vs their biologic counterparts are important concepts to utilizing these agents in oncology, according to a presentation given by Teresa Knoop, MSN, RN, AOCN, during the 5th Annual School of Nursing Oncology Meeting.

City of Hope, a world-renowned cancer research and treatment center, today announced that acclaimed Pacific Shores Medical Group has joined City of Hope.

Fam-trastuzumab deruxtecan-nxki significantly improved progression-free survival over ado-trastuzumab emtansine in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane, meeting the primary end point of the phase 3 DESTINY-Breast03 trial.

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.

The COVID-19 pandemic had a relatively limited effect on immuno-oncology research, according to results from the Association of Community Cancer Centers fourth annual analysis of the IO landscape.

The FDA has placed a partial clinical hold on clinical trials examining the combination of eprenetapopt and azacitidine in patients with myeloid malignancies.

Noa Biran, MD, discusses her predictions for where the field of multiple myeloma is headed as well as some of these agents that have generated excitement for patient populations that are currently an unmet need.

Refining treatment is not only a key aim of research in breast cancer but a greater possibility in the clinic with neoadjuvant and adjuvant PARP inhibitors, HER2 monoclonal antibodies, and greater stratification of genomic risk.

The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the biologics license application for eflapegrastimas a potential option for the management of chemotherapy-induced neutropenia.

TheraSphere Y-90 glass microspheres offer a precision medicine technique aimed at delivering high-dose radiation directly to tumors.

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

An association has been found in Latin American patients with lung adenocarcinoma between Native American ancestry and somatic landscape, including EGFR, KRAS, and STK11 mutations, as well as tumor mutational burden.

Avapritinib did not improve progression-free survival vs regorafenib in patients with unresectable or metastatic gastrointestinal stromal tumors, but the agent continues to be the most active available option for a subset of patients with PDGFRA D842V–mutant disease.

The FDA has granted an orphan drug designation to sotigalimab as a potential therapeutic option for patients with soft tissue sarcoma.

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

The combination of cemiplimab-rwlc plus platinum-doublet chemotherapy was found to significantly improve overall survival over chemotherapy alone in the frontline treatment of patients with advanced non–small cell lung cancer, meeting the primary end point of the phase 3 EMPOWER-Lung 3 trial.

Low-dose venetoclax monotherapy demonstrated antitumor activity in patients with heavily pretreated multiple myeloma and light chain amyloidosis harboring t(11;14).

The FDA has granted a priority review designation to a supplemental new drug application for cabozantinib for the treatment of patients with differentiated thyroid cancer who have progressed after previous therapy and who are radioactive iodine refractory.

Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge.

Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.

The combination of a CF33-CD19 oncolytic virus technology and CyCART-19, is under development for use as a potential therapeutic option for patients with solid tumors.

The combination of plinabulin plus docetaxel resulted in a statistically significant improvement in overall survival vs docetaxel alone when used in the second- or third-line treatment of patients with EGFR wild-type, non–small cell lung cancer and measurable lung lesions.